Business Wire

Keeper Security: New report reveals significant cybersecurity pressures on UK businesses

9.7.2021 10:00:00 EEST | Business Wire | Press release

Share

UK businesses are struggling to deal with multiple urgent cybersecurity challenges, new research by Keeper Security has revealed. The 2021 Cybersecurity Census Report shows cyberattacks are becoming more vicious, frequent and sophisticated, while UK businesses are underprepared and too slow to counter these attacks. As a result, senior leaders within UK organisations are preoccupied with playing a cyberattack blame game instead of investing in boosting their defences.

The report has found that more than nine in ten (92%) UK business suffered a cyberattack in the last 12 months and three quarters (78%) feel unprepared to deal with this threat. Nearly a third (31%) believe CTOs should take the blame in the case of a successful cyberattack. Such a weight of responsibility means cybersecurity standards are dropping: 36% of senior IT leaders confess to having kept a cyberattack to themselves, while 32% admit to using weak credentials such as ‘password’ or ‘admin’ to protect their data.

“UK businesses are clearly worried about their cybersecurity and, as our report has found, the challenges are manifold, affecting everything from budgets to productivity,” said Darren Guccione, CEO & co-founder, Keeper Security. “While there is a desire to boost security efforts, companies are facing many competing challenges right now and, understandably, might not always make cybersecurity investments a priority. Our report is an urgent reminder for organisations to proactively address their cybersecurity challenges as a priority since deferring them will make the consequences far more severe.”

Key findings include:

  • Almost all (92%) UK organisations are aware of gaps or weak links in their cybersecurity defences are, but less than half (40%) are actively addressing all of them
  • Two-thirds (66%) of UK organisations have relaxed their cybersecurity policies over the past 12 months so staff can work remotely or in order not to stifle productivity
  • 58% of IT professionals feel employees at their organisations do not understand the full consequences of poor cyber-hygiene
  • 61% of UK companies have a skills shortage in cybersecurity
  • The financial fallout of cyberattacks has been damaging, too, costing nearly one in ten (8%) UK businesses over £1 million
  • An overwhelming 87% of IT leaders support the creation of a nationwide governing body to hold businesses to account when it comes to best online security practices
  • And almost all (91%) are in agreement that UK businesses should be legally required to have basic cybersecurity protections in place to be allowed to operate

“Companies are struggling to put the right solutions in place to cope with cyberattacks and the consequences are both damaging and costly,” said Craig Lurey, CTO and co-founder, Keeper Security. “The conditions caused by Covid-19 have led to an increased amount of hybrid working, making effective cybersecurity defences even harder to achieve. But if businesses want to bounce back fully after the pandemic, they must get their security hygiene in order without delay.”

Despite the rise in cyberattacks and increasing pressures felt by security teams, more than a quarter of UK companies (28%) do not consider IT to be even in their top three priorities as they plan for the next 12 months. This is particularly worrying, given almost all (92%) UK organisations know where the gaps or weak links in their cybersecurity defences are but well under half (40%) are actively addressing them.

Guccione concludes: “While this situation can't be rectified overnight, there are straightforward steps UK businesses can take to boost their cyber defences. First, organisations should do a comprehensive cybersecurity audit, looking at where the gaps lie and how they can be addressed. Next, they need to put in place a clear plan of action for how to address these challenges. Running cybersecurity training sessions to educate employees and introducing a password management platform to keep credentials safe and secure are two simple, yet highly effective actions business can take today, to be better prepared against cyberattacks tomorrow.”

+++ ENDS +++

About Keeper Security Inc.

Keeper Security, Inc. (Keeper) is the highly-rated and patented cybersecurity platform for preventing password-related data breaches and cyberthreats. Keeper’s zero-knowledge security and encryption software is trusted by millions of people and thousands of businesses across the globe to mitigate the risk of cybertheft, boost employee productivity and meet compliance standards. Keeper has been named PC Magazine’s Best Password Manager of the Year & Editors’ Choice, PCWorld’s Editors’ Choice and is the winner of four G2 Best Software Awards and the InfoSec Award for Best Product in Password Management for SMB Cybersecurity. Keeper is SOC-2 and ISO 27001 Certified and is also listed for use by the U.S. federal government through the System for Award Management (SAM). Learn more at https://keepersecurity.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PR contact:
Tara Geoghegan
tara.geoghegan@archetype.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye